Issue 2, Volume 1


Cover Figure: Signal pattern consistent with BCR-ABL1 gene rearrangement.
See the article by Dun et al.

WASHINGTON, December 13,  2016 – Welcome to the “Advance Notice,”  newletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

Jamani et al report on the use of acyclovir combined with vaccination to reduce the incidence of herpes zoster reactivation and associated postherpetic neuropathy following allogeneic hematopoietic cell transplantation. These results could reduce the complications associated with this serious viral reactivation.

The report from Haribhai et al explores the role of platelets in inducing regulatory T cells through production of TGF-β. These studies further support the role of platelets as immune sensors that was highlighted in the Point-Counterpoint in the first issue of Blood Advances.

Idelalisib is an oral inhibitor of phosphatidylinositol-3-kinase δ with activity in patients with non-Hodgkin lymphoma. In the study by de Vos et al, idelalisib was combined with rituximab or bendamustine or both agents. The data demonstrate safety for these combinations that will need further testing for efficacy and safety given the challenges with this agent in other studies.

The central nervous system is a rare site of presentation of lymphoma. Treatment strategies vary using different modalities of therapy with or without cranial radiation. The article by Fallah et al reviews treatment options and outcomes for 9,165 patients with this disorder treated in the community over time, highlighting the changing patterns of treatment of this disease as reported to the US National Cancer Database.

Featured Visual Abstract

BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia

Karen A. Dun, Rob Vanhaeften, Tracey J. Batt, Louise A. Riley, Giuseppe Diano and Jan Williamson








Blood Advances is the official open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.